477312-33-7

Upstream product

• 218900-56-2 (S)-[1-(3-methoxyphenyl)ethyl]carbamic acid tert-butyl ester 
• 50919-07-8 (S)-1-(3-methoxyphenyl)ethylamine 
• 63720-38-7 3-hydroxy-(S)-α-phenethylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 266369-42-0 (S)-[1-(3-hydroxyphenyl)ethyl]carbamic acid tert-butyl ester 

Downstream Products

• 878805-35-7 t-butyl ((1S)-1-{3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}ethyl)carbamate 
• 477312-35-9 (S)-[1-(3-morpholin-4-yl-phenyl)ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers

A new class of acrylamides was synthesized, and the effects of these analogues on outward potassium current were evaluated by using two electrode voltage clamp recordings from Xenopus laevis oocytes expressing cloned mKCNQ2 channels. SAR studies indicated that the pharmacophore of the acrylamide series includes the (S) absolute configuration at the (1-phenyl)ethyl moiety and the α,β-unsaturated acrylamide functionality with a free NH. This study identified (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide ((S)-1) and (S)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-ethyl]-3- (4-fluoro-phenyl)-acrylamide ((S)-2) as KCNQ2 openers for further electrophysiological evaluations. These two acrylamides demonstrated significant activity in the cortical spreading depression model of migraine as we reported previously.